A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)

NCT01662063 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

218

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Tocilizumab

Sponsor

Genentech, Inc.